Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: High-dose chemotherapy with autologous stem cell transplantation
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

High-dose chemotherapy with autologous stem cell transplantation

1 evidence topic · 1 source

Thiotepa-based consolidation

“consolidative HDC/ASCT, preferably conditioned by a thiotepa-based regimen” (opens the source at this quote in a new tab)